Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; RT-116 which is in discovery stage for the treatment of obesity; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California. Show more
Location: 2051 Ringwood Avenue, San Jose, CA, 95131, United States | Website: https://www.ranitherapeutics.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
35.43M
52 Wk Range
$0.39 - $3.75
Previous Close
$0.49
Open
$0.48
Volume
769,831
Day Range
$0.44 - $0.48
Enterprise Value
34.65M
Cash
10.22M
Avg Qtr Burn
-7.753M
Insider Ownership
19.56%
Institutional Own.
17.00%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Phase 2 Update | ||
RT-111 (RaniPill® capsule) Details Psoriasis, Skin disease/disorder | Phase 1 Update | |
Phase 1 Initiation |